The potential for circulating microRNAs in the diagnosis of myocardial infarction: A novel approach to disease diagnosis and treatment

Current Pharmaceutical Design

Volumn 22, Issue 3, 2016, Pages 397-403

  Gholamin, Sharareh ^b   Pasdar, Alireza ^a,c   Khorrami, Mohammad Sadegh ^a   Mirzaei, Hamed ^a   Mirzaei, Hamid Reza ^d   Salehi, Rasoul ^e   Ferns, Gordon A ^f   Ghayour Mobarhan, Majid ^a   Avan, Amir ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Stanford California and Cofounder   (United States)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Biomarkers; Circulating miRNAs; Diagnosis; Myocardial infarction

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 1; MICRORNA 133; MICRORNA 208; MICRORNA 24; MICRORNA 499; TROPONIN; UNCLASSIFIED DRUG; TROPONIN T;

APOPTOSIS; CARDIOVASCULAR DISEASE; DIAGNOSTIC APPROACH ROUTE; EXOSOME; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; STRESS; ANIMAL; BLOOD; CARDIAC MUSCLE CELL; DRUG EFFECTS; EARLY DIAGNOSIS; GENE EXPRESSION; GENETICS; MOLECULARLY TARGETED THERAPY; MYOCARDIAL INFARCTION; PATHOLOGY;

ANIMALS; APOPTOSIS; BIOMARKERS; EARLY DIAGNOSIS; GENE EXPRESSION; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; TROPONIN T;

EID: 84962594113     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151112151924     Document Type: Review

References (109)

1. White HD, Chew DP. Acute myocardial infarction. Lancet 2008; 372: 570-84.
2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014; 129: e28-292.
3. Sayed AS, Xia K, Salma U, et al. Diagnosis, prognosis and therapeutic role of circulating miRNAs in cardiovascular diseases. Heart Lung Circ 2014; 23: 503-10.
4. Thygesen K, Alpert JS, White HD. White. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50: 2173-95.
5. Jaffe AS, Babuin L, Apple FS. Apple. Biomarkers in acute cardiac disease: the present and the future, J Am Coll Cardiol 2006; 48: 1-11.
6. de Winter RJ, Koster RW, Sturk A, et al. Value of myoglobin, troponin T, and CK-MBmass in ruling out an acute myocardial infarction in the emergency room. Circulation 1995; 92: 3401-7.
7. Devaux Y, Stammet P, Friberg H, et al. MicroRNAs: new biomarkers and therapeutic targets after cardiac arrest?. Crit Care 2015; 19: 54.
8. McCord J, Nowak RM, McCullough PA, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001; 104: 1483-8.
9. McCann CJ, Glover BM, Menown IB, et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J 2008 ; 29: 2843-50.
10. Plebani M, Zaninotto M. Diagnostic strategies in myocardial infarction using myoglobin measurement. Eur Heart J 1998; 19: N12-5.
11. Jaffe AS, Ravkilde J, Roberts R, et al. It’s time for a change to a troponin standard, Circulation 2000; 102: 1216-20.
12. Bartel DP, MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
13. V. Ambros. The functions of animal microRNAs. Nature 2004; 431: 350-5.
14. Plasterk RH. Micro RNAs in animal development. Cell 2006; 124: 877-81.
15. J. C. Carrington, V. Ambros. Role of microRNAs in plant and animal development. Science 2003; 301: 336-8.
16. W. P. Kloosterman, R. H. Plasterk. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-50.
17. B. Lindahl. Acute coronary syndrome-the present and future role of biomarkers. Clin Chem Lab Med 2013; 51: 1699-706.
18. Chim SS, Shing TK, Hung EC, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008; 54: 482-90.
19. Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31: 659-66.
20. Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011; 51: 872-5.
21. Kaudewitz D, Lee R, Willeit P, et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Haemost 2013; 110: 609-15.
22. Laterza OF, Lim L, Garrett-Engele PW, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009; 55: 1977-83.
23. Hornby RJ, Starkey Lewis P, Dear J, et al. MicroRNAs as potential circulating biomarkers of drug-induced liver injury: key current and future issues for translation to humans. Expert Rev Clin Pharmacol 2014; 7: 349-62.
24. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106: 4402-7.
25. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-5.
26. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
27. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
28. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-8.
29. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-33.
30. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by highdensity lipoproteins. Nat Cell Biol 2011; 13: 423-33.
31. Gallo A, Tandon M, Alevizos I, et al. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012; 7: e30679.
32. Lindner K, Haier J, Wang Z, et al. Circulating microRNAs: emerging biomarkers for diagnosis and prognosis in patients with gastrointestinal cancers. Clin Sci 2015; 128: 1-15.
33. O’Sullivan JF, Neylon A, McGorrian C, et al. MicroRNA expression in coronary artery disease. MicroRNA 2013; 2: 205-11.
34. Köberle V, Pleli T, Schmithals C, et al. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One 2013; 8: e75184.
35. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-9.
36. Bihrer V, Friedrich-Rust M, Kronenberger B, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011; 106: 1663-9.
37. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
38. Velu VK, Ramesh R, Srinivasan A. Circulating microRNAs as biomarkers in health and disease, Journal of clinical and diagnostic research. J Clin Diagn Res 2012; 6: 1791-5.
39. Devaux Y, Mueller M, Haaf P, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain, Journal of internal medicine. J Intern Med 2015; 277: 260-71.
40. Cheng Y, Tan N, Yang J, et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci 2010; 119: 87-95.
41. Oikonomou E, Siasos G, Tousoulis D, et al. Diagnostic and therapeutic potentials of microRNAs in heart failure. Curr Top Med Chem 2013; 13: 1548-58.
42. Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31: 659-66.
43. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?. Circ Res 2012; 110: 483-95.
44. Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease, Circulation. Circ Cardiovasc Genet 2010; 3: 499-506.
45. Cheng Y, Tan N, Yang J, et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci 2010; 119: 87-95.
46. D’Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31: 2765-73.
47. van Rooij E, Quiat D, Johnson BA, et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 2009; 17: 662-73.
48. Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677-84.
49. Devaux Y, Vausort M, Goretti E, et al. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem 2012; 58: 559-67.
50. Xiao J, Shen B, Li J, et al. Serum microRNA-499 and microRNA-208a as biomarkers of acute myocardial infarction. Int J Clin Exp Med 2014; 7: 136-41.
51. Wang R, Li N, Zhang Y, et al. Circulating microRNAs are promising novel biomarkers of acute myocardial infarction. Intern Med 2011; 50: 1789-95.
52. Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 2011; 4: 446-54.
53. Meder B, Keller A, Vogel B, et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 2011; 106: 13-23.
54. Qian L, Van Laake LW, Huang Y, et al. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med 2011; 208: 549-60.
55. Wang J, Huang W, Xu R, et al. MicroRNA_24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 2012; 16: 2150-60.
56. Van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105: 13027-32.
57. Port JD, Walker LA, Polk J, et al. Temporal expression of miRNAs and mRNAs in a mouse model of myocardial infarction. Physiol Genomics 2011; 43: 1087-95.
58. Wang F, Long G, Zhao C, et al. Atherosclerosis-related circulating miRNAs as novel and sensitive predictors for acute myocardial infarction. PLoS One 2014; 9: e105734.
59. Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 2014; 124: 2136-46.
60. Roy S, Khanna S, Hussain SR, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009; 82: 21-9.
61. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105: 13027-32.
62. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-4.
63. Cardin S, Guasch E, Luo X, et al. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure, Circulation. Circ Arrhythm Electrophysiol 2012; 5: 1027-35.
64. Peng L, Chun-guang Q, Bei-fang L, et al. Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction. Diagn Pathol 2014; 9: 89.
65. Jayawardena TM, Egemnazarov B, Finch EA, et al. MicroRNAmediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 2012; 110: 1465-73.
66. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13: 613-8.
67. Meder B, Keller A, Vogel B, et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 2011; 106: 13-23.
68. Maurel M, Dejeans N, Taouji S, et al. MicroRNA-1291-mediated silencing of IRE1alpha enhances Glypican-3 expression. RNA 2013; 19: 778-88.
69. Marchand A, Proust C, Morange PE, et al. miR-421 and miR-30c inhibit SERPINE 1 gene expression in human endothelial cells. PLoS One 2012; 7: e44532.
70. Xin M, Small EM, Sutherland LB, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009; 23: 2166-78.
71. Wang J, Jia Z, Zhang C, et al. miR-499 protects cardiomyocytes from H 2O 2-induced apoptosis via its effects on Pdcd4 and Pacs2. RNA Biol 2014; 11: 339-50.
72. Nabialek E, Wanha W, Kula D, et al. Circulating microRNAs (miR-423-5p, miR-208a and miR-1) in acute myocardial infarction and stable coronary heart disease. Minerva Cardioangiol 2013; 61: 627-37.
73. Lu HQ, Liang C, He ZQ, et al. Circulating miR-214 is associated with the severity of coronary artery disease. J Geriatr Cardiol 2013; 10: 34-8.
74. Shi B, Guo Y, Wang J, et al. Altered expression of microRNAs in the myocardium of rats with acute myocardial infarction. BMC Cardiovasc Disord 2010; 10: 11.
75. Zhong J, He Y, Chen W, et al. Circulating microRNA-19a as a potential novel biomarker for diagnosis of acute myocardial infarction. Int J Mol Sci 2014; 15: 20355-64.
76. Qin X, Wang X, Wang Y, et al. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. Proc Natl Acad Sci 2010; 107: 3240-4.
77. Huang Y, Qi Y, Du JQ, Zhang DF. MicroRNA-34a regulates cardiac fibrosis after myocardial infarction by targeting Smad4. Expert Opin Ther Targets 2014; 18(12): 1355-65.
78. Li Z, Lu J, Luo Y, Li S, Chen M. High association between human circulating microRNA-497 and acute myocardial infarction. Sci World J 2014; 2014: 931845.
79. He F, Lv P, Zhao X, et al. Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. Mol Cell Biochem 2014; 394: 137-44.
80. Mao J, Lv Z, Zhuang Y. MicroRNA-23a is involved in tumor necrosis factor-alpha induced apoptosis in mesenchymal stem cells and myocardial infarction. Exp Mol Pathol 2014; 97: 23-30.
81. Meloni M, Marchetti M, Garner K, et al. Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction, Molecular therapy. Mol Ther 2013; 21: 1390-402.
82. Fiedler J, Jazbutyte V, Kirchmaier BC, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011; 124: 720-30.
83. Wang J, Huang W, Xu R, et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 2012; 16: 2150-60.
84. Qian L, Van Laake LW, et al. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med 2011; 208: 549-60.
85. Devaux Y, Vausort M, McCann GP, et al. MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction. Circ Cardiovasc Genet 2013; 6: 290-8.
86. Kondkar AA, Abu-Amero KK. Utility of circulating MicroRNAs as clinical biomarkers for cardiovascular diseases. Biomed Res Int 2015; 2015: 821823.
87. Long G, Wang F, Duan Q, et al. Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction. Int J Biol Sci 2012; 8: 811-8.
88. Kumarswamy R, Lyon AR, Volkmann I, et al. SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur Heart J 2012; 33: 1067-75.
89. Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007; 13: 486-91.
90. Shan ZX, Lin QX, Fu YH, et al. Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res Commun 2009; 381: 597-601.
91. Shan ZX, Lin QX, Deng CY, et al. miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett 2010; 584: 3592-600.
92. Shi L, Fisslthaler B, Zippel N, et al. MicroRNA-223 antagonizes angiogenesis by targeting beta1 integrin and preventing growth factor signaling in endothelial cells. Circ Res 2013; 113: 1320-30.
93. Hullinger TG, Montgomery RL, Seto AG, et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 2012; 110: 71-81.
94. Pan Z, Sun X, Shan H, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 2012; 126: 840-50.
95. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324: 1710-3
96. Li Q, Xie J, Li R, et al. Overexpression of microRNA-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction. J Cell Mol Med 2014; 18: 919-28.
97. Boon RA, Dimmeler S. MicroRNAs in myocardial infarction, Nature reviews. Nat Rev Cardiol 2015; 12: 135-42.
98. Rane S, He M, Sayed D, et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009; 104: 879-86.
99. Barile L, Lionetti V, Cervio E, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res 2014; 103: 530-41.
100. Ong SG, Lee WH, Huang M, et al. Cross talk of combined gene and cell therapy in ischemic heart disease: role of exosomal microRNA transfer. Circulation 2014; 130: S60-9.
101. Ekhteraei-Tousi S, Mohammad-Soltani B, Sadeghizadeh M, et al. Inhibitory effect of hsa-miR-590-5p on cardiosphere-derived stem cells differentiation through downregulation of TGFB signaling. J Cell Biochem 2015; 116: 179-91.
102. Katare R, Riu F, Mitchell K, et al. Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ Res 2011; 109: 894-906.
103. Zidar N, Bostjancic E, Glavac D, et al. MicroRNAs, innate immunity and ventricular rupture in human myocardial infarction. Dis Markers 2011; 31: 259-65.
104. O’Connell RM, Rao DS, Chaudhuri AA, et al. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010; 10: 111-22.
105. Zhu H, Yang Y, Wang Y, et al. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc Res 2011; 92(1): 75-84.
106. Hu S, Huang M, Nguyen PK, et al. Novel microRNA prosurvival cocktail for improving engraftment and function of cardiac progenitor cell transplantation. Circulation 2011; 124: S27-34.
107. Tolonen AM, Magga J, Szabo Z, et al. Serpi, Inhibition of Let-7 microRNA attenuates myocardial remodeling and improves cardiac function postinfarction in mice. Pharmacol Res Perspect 2014; 2: e00056.
108. Zhang X, Wang X, Zhu H, et al. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. J Mol Cell Cardiol 2010; 49: 841-50.
109. Santaló Bel M, Guindo Soldevila J, Ordóñez Llanos J. Biological markers of myocardial necrosis. Rev Esp Cardiol 2003; 56: 703-20.